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The research described here was aimed at the selection of oral bacteria that displayed properties compatible
with their potential use as probiotics for the pharyngeal mucosa. We included in the study 56 bacteria newly
isolated from the pharynges of healthy donors, which were identified at the intraspecies level and characterized
in vitro for their probiotic potential. The experiments led us to select two potential probiotic bacterial strains
(Streptococcus salivarius RS1 and ST3) and to compare them with the prototype oral probiotic S. salivarius
strain K12. All three strains efficiently bound to FaDu human epithelial pharyngeal cells and thereby antag-
onized Streptococcus pyogenes adhesion and growth. All were sensitive to a variety of antibiotics routinely used
for the control of upper respiratory tract infections. Immunological in vitro testing on a FaDu layer revealed
different responses to RS1, ST3, and K12. RS1 and ST3 modulated NF-B activation and biased proinflam-
matory cytokines at baseline and after interleukin-1 (IL-1) induction. In conclusion, we suggest that the
selected commensal streptococci represent potential pharyngeal probiotic candidates. They could display a
good degree of adaptation to the host and possess potential immunomodulatory and anti-inflammatory
properties.
Metagenomics and functional molecular immunology sub-
stantiate the interpretation of humans as holobionts, in the
sense of functional superorganisms, combining the self and
microbes acting in concert to produce phenomena governed by
the collective (25, 42). The association between host and
symbionts affects the fitness of the holobiont within its en-
vironment, and it often governs the physiological homeosta-
sis of the narrow balance between host well being and dys-
function (13, 35).
The mechanisms underlying the cross talk between a human
host and microbes are only marginally understood. Their elu-
cidation at a molecular level could supply the theoretical bases
to develop strategies for preventing or treating several human
dysfunctions, such as autoimmune diseases, through the recon-
stitution of a proper human-microbe mutualism.
The probiotic approach, in its widest sense, falls into this
context, since it consists of the modification of a human mi-
crobiota by exogenous administration of microbial cells (or cell
components), aimed at benefiting the host’s health. A most
commonly accepted definition comes from FAO/WHO, which
states that probiotics are “live microorganisms which when
administered in adequate amounts confer a health benefit on
the host” (17).
So far, probiotics have been most predominantly investi-
gated for and applied to the intestinal tract. Nevertheless, a
few applications beyond the gut have proposed the potential
beneficial role of probiotics for the stomach (23), vaginal mu-
cosa (36), urinary tract (6), skin (27), and oral cavity (39). With
respect to oral probiotics, particularly noticeable are the stud-
ies done by J. R. Tagg and coworkers of Streptococcus salivarius
strain K12. Tagg and others, in fact, showed that, following oral
administration, the bacterial strain K12 can colonize the oral
mucosae of infants and adults (20, 34), downregulate the in-
nate immune responses of human epithelial cells (11), and
reduce oral volatile sulfur compound levels (8). Strain K12 was
also revealed to produce two plasmid-encoded lantibiotic pep-
tides (22, 38) that are active against Streptococcus pyogenes, the
main etiological agent of bacterial pharyngitis. These investi-
gations demonstrated the potential effectiveness of the probi-
otic intervention in the oropharyngeal tract.
Encouraged by the promising results obtained in J. R. Tagg’s
experiments, in the present study, we screened oral bacteria for
their potential use as probiotics in the pharyngeal mucosa. We
tested the ability of bacteria, which were newly isolated from
the pharynges of healthy volunteers, to adhere to a human
pharyngeal cell layer and to antagonize S. pyogenes on two
different epithelial cell lines. The study allowed the selection of
two bacterial strains, which were further investigated from an
immunological point of view for their ability to cross talk with
human epithelial cells in vitro.
MATERIALS AND METHODS
Isolation of bacteria from pharyngeal mucosa, bacterial strains, and culture
conditions. To isolate bacteria from the pharynx, specimens were collected using
polyester fiber-tipped applicator swabs (VWR, Milan, Italy) taken from 4 healthy
donors (3 females at 58, 32, and 29 years old, and a 32-year-old male). After
serial dilutions in 0.1% peptonized saline, specimens were plated on MRS agar
(Fluka Feinchemikalien GmbH, Neu-Ulm, Germany) supplemented with 0.05%
cysteine-HCl (cMRS), M17 (Fluka Feinchemikalien GmbH) containing 2% lac-
tose (LM17), and 2% glucose-tryptic soy agar (Difco, Detroit, MI). All 56
colonies grown at the highest dilutions were picked and spread on a plate with a
loop. This procedure was repeated at least four times in order to obtain pure
cultures. Table 1 lists the oral bacterial isolates used in this study. If not differ-
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ently specified, oral streptococci and Streptococcus thermophilus DSM20617T
were routinely grown overnight at 37°C in LM17, while Streptococcus pyogenes
was grown overnight at 37°C in brain heart infusion (BHI) medium (Difco,
Detroit, MI) supplemented with 0.3% yeast extract (yeBHI). S. pyogenes C11 has
been clinically isolated from a pharyngitis patient and has been ascribed to emm
type 77 through emm gene sequence analysis (data not shown).
Identification and molecular characterization of bacterial isolates. The iso-
lates from each subject have been clustered by means of a BOX-PCR assay
(Table 1), which was performed with the primer BoxA1 (5-CTACGGCAAGG
CGACGCTGACG-3).
The 16S rRNA gene was amplified from at least one representative isolate
from each BOX genotypic group (Table 1) by PCR, using primers P0 (5-GAA
GAGTTTGATCCTGGCTCAG-3) and P6 (5-CTACGGCTACCTTGTTACG
A-3). The resulting amplicons (each about 1.5 kb long) were then completely
sequenced. Streptococcus salivarius isolates were further characterized by ran-
dom amplified polymorphic DNA (RAPD) analysis, performed with primers
OPI17 (5-CGAGGGTGGTGATC-3), OPI02-mod (5-GCTCGGAGGAGAG
G-3), M13 (5-GTAAAACGACGGCCAGT-3), and PedAF (5-ATACTACG
GTAATGGGGT-3).
A similarity dendrogram was built using NTSYSpc version 2.01 (Applied
Biostatistics Inc., NY).
In vitro cultivation of epithelial cell lines. FaDu (human pharynx carcinoma
cell line; ATCC HTB-43) and HaCaT (human keratinocytes from a spontaneous
immortalized, nontumorigenic cell line) cells were routinely grown in 24-well
tissue culture plates in Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 10% (vol/vol) heat-inactivated fetal calf serum (30 min at 56°C), 100
U ml1 penicillin, 100 g ml1 streptomycin, 0.1 mM nonessential amino acids,
2 mM L-glutamine and incubated at 37°C in a water-jacketed incubator in an
atmosphere of 95% air and 5% carbon dioxide, until a confluent monolayer was
formed.
Bacterial adhesion to the FaDu cell layer. FaDu cells were grown in 3-cm petri
plates on microscope cover glasses as described above. Cell monolayers were
carefully washed with phosphate-buffered saline (PBS; pH 7.3) before bacterial
cells were added. The bacterial cell concentration of an overnight culture was
determined microscopically with a Neubauer-improved counting chamber
(Marienfeld GmbH, Lauda-Ko¨nigshofen, Germany). Approximately 2  108
cells of each strain resuspended in PBS (pH 7.3) were incubated with a mono-
layer of FaDu cells. After 1 h at 37°C, all monolayers were washed three times









IS IS-A1 IS1 cMRS S. salivarius
IS8, IS10, IS12 LM17
IS-A2 IS5, IS6 LM17 S. salivarius
IS7 gTSA
IS-B IS3, IS4 cMRS S. sanguinis
IS-C IS9 LM17 Staphylococcus aureus
IS15 gTSA
IS-D IS11, IS13 LM17 Rothia mucilaginosa
IS14 gTSA
RS RS-A1 RS1, RS8, RS10 LM17 S. salivarius
RS3, RS6 cMRS
RS13, RS14 gTSA
RS-A2 RS9 LM17 S. salivarius
RS-B RS4 cMRS Alloscardovia omnicolens
RS-C RS5 cMRS Lactococcus lactis subsp. lactis his
RS-D RS11 LM17 Micrococcus sp. (M. luteus)
RS-E RS12 gTSA Rothia mucilaginosa
RS-F RS15 gTSA Bacillus subtilis
SM SM-A1 SM1, SM2, SM4, SM5 cMRS S. salivarius
SM6, SM8, SM9 LM17 S. salivarius
SM11, SM14, SM15 gTSA S. salivarius
SM-A2 SM12 gTSA S. salivarius
SM-B SM3 cMRS S. oralis gdh
SM-C SM7 LM17 Rothia mucilaginosa
SM-D SM13 gTSA Neisseria sp. (N. subflava)
ST ST-A1 ST3 cMRS S. salivarius
ST-A2 ST12 LM17 S. salivarius
ST-B ST2, ST5p cMRS S. oralis gdh
ST-C ST5g cMRS S. sanguinis
ST-D ST4 cMRS S. oralis gdh
ST15 gTSA
ST-E ST7, ST11 LM17 S. infantis gdh
ST-F ST1, ST8 LM17 Bacillus sp. (B. cereus)
ST-G ST9 LM17 S. oralis gdh
ST-H ST6 cMRS Staphylococcus epidermidis
ST-I ST13, ST14 gTSA Rothia mucilaginosa
a Similar (but not identical) BOX-PCR electrophoretic patterns are indicated with the same letter but a different number.
b Representative strains chosen for 16S rRNA gene sequence analysis are in boldface. Representative isolates were deposited in the culture collection of the
Department of Food Science and Microbiology, Industrial Microbiology Section, University of Milan, Italy (MIM culture collection).
c Species designations in parentheses refer to those with 16S rRNA gene sequence similarities below 95%.
d gdh, taxonomic identification based on the sequence of an approximately 500-bp internal fragment of the glucose-6-phosphate dehydrogenase gene (gdh) (5); his,
taxonomic identification based on the length polymorphism of a PCR-amplified fragment from a histidine biosynthesis operon (4).
e gTSA, 2% glucose-tryptic soy agar.
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with PBS to release unbound bacteria. Cells were then fixed with 3 ml of
methanol and incubated for 8 min at room temperature. After methanol was
removed, cells were stained with 3 ml of Giemsa stain solution (1:20; Carlo Erba,
Milan, Italy) and left for 30 min at room temperature. Wells were then washed
until no color was observed in the washing solution and dried in an incubator at
30°C for 1 h. Microscope cover glasses were then removed from the petri plate
and examined microscopically (magnification of 100) immersed in oil. Adher-
ent bacteria in 20 randomly selected microscopic fields were counted and aver-
aged.
Preparation of bioluminescent Streptococcus pyogenes. Reporter vector
pCSS945, carrying a phage T5 promoter-lac operator upstream of the insect
luciferase gene lucGR (29), was used to obtain the luminescent phenotype in
Streptococcus pyogenes C11, according to conventional electrotransformation
methods. Transformants were selected on yeBHI agar plates with 5 g ml1 of
chloramphenicol. The selected luminescent S. pyogenes clone was named
C11LucFF.
Antagonistic activity against Streptococcus pyogenes. The antagonism against S.
pyogenes was studied through exclusion and competition assays. Exclusion con-
sisted of an hour of preincubation of the FaDu layer with 1 ml of a tester strain
suspension (5  108 cells ml1), followed by a washing step with PBS and
incubation with 1 ml of the indicator strain (S. pyogenes C11LucFF) suspension
(2  108 cells ml1) for 1 h. The concentration of 5  108 tester cells ml1 was
chosen because it corresponded to the plateau of dose-response curves which
were prepared during the setup of the experiment by measuring the antagonistic
activity as a function of tester cell concentration (data not shown). Competition
consisted of an hour of coincubation of the same number of tester and indicator
strains (2  108 cells ml1).
The bacterial cell concentration was determined from an overnight culture
microscopically by means of a Neubauer-improved counting chamber (Marien-
feld GmbH). After incubation, FaDu layers were quickly washed twice with 1 ml
PBS (pH 7.3), and D-luciferin (Sigma-Aldrich, Steinheim, Germany) was added
at the concentration of 12.5 M in citrate buffer, pH 5. Immediately, the lumi-
nescence signal was measured with a Victor 3 luminometer (PerkinElmer,
Monza, Italy). Each tester strain was analyzed in triplicate with at least two
independent experiments. An unpaired Student’s t test was performed to find
statistically significant differences.
Antibacterial activity against Streptococcus pyogenes and PCR detection of
bacteriocin-encoding genes. In the first set of experiments, tester bacterial strains
were spread with a loop on an agar plate containing LM17 medium and incu-
bated overnight at 37°C. Then, 15 ml of soft yeBHI agar containing about 106
cells of the indicator strain (S. pyogenes C11) was poured over the plates. The
plates were checked for inhibition zones after incubation at 37°C for 24 and 48 h.
The production of antimicrobial substances was also tested through disk diffu-
sion. Briefly, tester strains were grown until stationary growth phase in LM17
medium. Culture supernatants were neutralized to pH 7, filter sterilized, and
spotted (0.1 ml) on a filter paper disk, which was previously placed on yeBHI soft
agar plates inoculated with about 106 S. pyogenes cells. The presence of an
inhibition halo was checked after 24 and 48 h.
The PCRs used to detect previously characterized bacteriocin structural genes
(salivaricin A, salivaricin B, streptin, and peptide SA-FF22) were performed as
described by Wescombe et al. (41).
Stimulation of FaDu monolayers and enzyme-linked immunosorbent assay
(ELISA) measurement of cytokine production. Human pharyngeal carcinoma
cells (FaDu) were seeded into 24-well plates and grown, as previously described.
Bacterial cells were added to monolayers of FaDu cells in 0.5 ml of fresh
antibiotic-free Eagle’s minimum essential medium (EMEM) containing 100 mM
HEPES (pH 7.4) and incubated overnight at 37°C. Each bacterial strain was used
at a multiplicity of infection (MOI) of about 1,000, while EMEM/HEPES me-
dium without bacterial cells was used as a control. After overnight incubation,
the supernatants were collected by pipetting, centrifuged to remove cells, and
kept at 80°C. The same experiment was also performed by incubating bacteria
and FaDu cells in the presence of 2 ng ml1 of interleukin-1 (IL-1). Finally,
different cytokines in the supernatants were determined with a Bio-Plex array
reader (Luminex 100; Bio-Rad Laboratories, Hercules, CA) using the Bio-Plex
human cytokine 17-plex panel (Bio-Rad), according to the human cytokine
Bio-Plex panel assay protocol (Bio-Rad). The list of tested cytokines and the
corresponding detection limits were as follows: IL-1, 0.3 pg ml1; IL-2, 0.2 pg
ml1; IL-4, 0.1 pg ml1; IL-5, 0.3 pg ml1; IL-6, 0.2 pg ml1; IL-7, 0.3 pg ml1;
IL-8, 0.3 pg ml1; IL-10, 0.2 pg ml1; IL-12 (p70), 0.4 pg ml1; IL-13, 0.3 pg
ml1; IL-17, 0.5 pg ml1; granulocyte colony-stimulating factor (G-CSF), 0.2
pg ml1; granulocyte-macrophage colony-stimulating factor (GM-CSF), 1.1 pg
ml1; gamma interferon (IFN-), 2.6 pg ml1; monocyte chemotactic protein 1
(MCP-1), 0.8 pg ml1; macrophage inflammatory protein 1 (MIP-1), 0.6 pg
ml1; and tumor necrosis factor alpha (TNF-), 0.6 pg ml1.
Construction of stable NF-B reporting FaDu cells. Stable transfectants of the
FaDu cell line were obtained after transfection with the plasmid pNiFty2-Luc
(InvivoGen, Rho, Italy). This plasmid combines five NF-B sites with the insect
luciferase reporter gene luc. The presence of active NF-B molecules in the cell
activates the promoter, resulting in the expression of the luciferase gene. Trans-
fection was performed by means of the StoS transfection kit (GeneSpin, Milan,
Italy), in accordance with the manufacturer’s protocol. Afterward, cells were
resuspended in fresh DMEM, seeded in 24-well plates, and incubated for 48 h,
in order to obtain the expression of the antibiotic resistance. Finally, stable
recombinant clones were selected by adding into the culture medium 50 g ml1
of zeocin (InvivoGen, Rho, Italy).
Study of NF-B activation. Recombinant FaDu cells were cultured using the
same protocol as that used for nontransfected FaDu cells, in the presence of 50
g ml1 of zeocin. After growth, the FaDu layer was detached by trypsinization,
and cells were resuspended in DMEM at a concentration of 250,000 cells ml1
in the presence of 100 mM HEPES (pH 7.4). Subsequently, 50 l of tester
bacterial suspension, containing 2  109, 2  108, or 2  107 cells ml1, was
added to 450 l of a FaDu suspension, resulting in MOIs of about 1,000, 100, or
10, respectively. After incubation at 37°C for 4 h, samples were kept in ice and
sonicated at maximum frequency for 5 s (Bandelin sonicator; Bandelin electronic
GmbH & Co., Berlin, Germany). Bacterial cells and insoluble particles were
removed by centrifugation, and the supernatants were transferred into a new
tube. At this point, 100 l of supernatants was aliquoted in duplicate into the
wells of a 96-well white microtiter plate (PerkinElmer, Monza, Italy); then, 12.5
l of a 10 mM ATP solution and 12.5 l of 0.1 mM D-luciferin were added, and
the emitted bioluminescence was immediately recorded every 90 s with a Victor
3 luminometer (PerkinElmer). The maximum of the light production curve was
considered for comparison of the results. In a different set of experiments,
recombinant FaDu cells were simultaneously stimulated with IL-1 (2 ng ml1).
In the setup of the experiment, we confirmed that IL-1 was not modified or
digested by bacteria during the incubation step (data not shown). All strains were
analyzed in duplicate in at least three independent experiments per each single
MOI. An unpaired Student’s t test was performed to find statistically significant
differences.
Antibiotic susceptibility of selected bacteria. The inhibitory concentrations of
several antimicrobial agents were determined, according to conventional broth
microdilution protocols, in commercial 96-well microtiter plates for the following
concentration ranges: ampicillin, chloramphenicol, erythromycin, oxytetracy-
cline, and vancomycin, 1 to 16 g ml1; gentamicin, 8 to 64 g ml1; and
kanamycin and streptomycin, 16 to 128 g ml1. The following three different
liquid media were used in this experiment: LM17, MRS, and BHI.
Determination of urease activity and PCR detection of the ureC gene. Urease
activity was tested by evaluating the release of ammonia by means of the phenol
red assay, as described in the literature (28).
The amplification of the gene coding for the main subunit of the urease
complex (ureC) was carried out as previously described (31), using primers
ureIAf (5-GGAATTGTAACAGCTTGGAT-3) and ureCr (5-GTCGTATGG
ATTGGTTCACA-3).
RESULTS
Isolation and characterization of bacteria from pharyngeal
mucosa. A total of 56 isolates were obtained from pharyngeal
swab samples taken from four healthy donors by using three
different culture media (Table 1). After a preliminary grouping
of all isolated bacteria through BOX-PCR fingerprinting (data
not shown), 16S rRNA genes sequence analysis revealed that
39 of the isolates belonged to the Streptococcus genus. Strep-
tococcus salivarius was the most represented species (28 iso-
lates). We also isolated Streptococcus oralis (6 isolates) and
Streptococcus infantis (2 isolates), which were distinguished by
glucose-6-phosphate dehydrogenase gene (gdh) sequence anal-
ysis (5). The only species isolated from all four pharyngeal
samples were S. salivarius and Rothia mucilaginosa (7 isolates).
All the other bacteria are listed in Table 1.
Streptococcus salivarius isolates were further characterized at
the intraspecies level by means of BOX-PCR and RAPD-PCR
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analyses (data not shown). A computer evaluation of similar-
ities and clustering resulted in a total of 11 unique S. salivarius
genotypes out of 28 pharyngeal isolates and the K12 commer-
cial probiotic strain (Fig. 1). The isolates that were included in
a single genotypic group originated from the same pharyngeal
sample, suggesting that they were probably multiple isolates.
Several oral isolates adhere efficiently to the FaDu epithelial
layer. Twenty-three bacterial strains were tested for their abil-
ity to adhere to the FaDu epithelial cell layer. We studied 13 S.
salivarius strains, including at least one representative isolate
from each genotypic cluster and the commercial probiotic
strain K12. We also included 10 other pharyngeal isolates that
were arbitrarily selected. After being extensively washed with
PBS, a significant proportion of cells from many bacterial
strains remained attached to the FaDu monolayer, providing
evidence that the adhesion was not only nonspecific physical
entrapment. In particular, the following three strains displayed
strong adhesive phenotypes, coinciding with an adhesion index
(ADI; bacterial cells per 100 FaDu cells) of more than 2,500
(Fig. 2): Lactococcus lactis subsp. lactis RS5, S. salivarius K12,
and S. salivarius ST3. Good adhesive ability was also displayed
by nine other strains (ADI between 2,500 and 500), all belong-
ing to the species S. salivarius.
The antagonistic activity against Streptococcus pyogenes on
human epithelial cell lines is strain dependent. All the oral S.
salivarius strains studied in the adhesion assay, together with
the other bacteria displaying a significant adhesion on the
FaDu cell layer (Fig. 2), were investigated with a three-com-
ponent system consisting of the epithelial cell layer, the S.
pyogenes C11LucFF indicator bioluminescent strain, and the
tester bacterium. In this experiment, we measured the reduc-
tion of bioluminescence produced by S. pyogenes C11LucFF as
an indication of the antagonistic activity exerted by the tester
strains.
Antagonism through exclusion was tested on the layers of
two different human epithelial cell lines, FaDu and HaCaT.
The results showed that antagonistic exclusion against S. pyo-
genes C11LucFF was generally stronger on FaDu hypopharyn-
geal carcinoma cells than HaCaT keratinocytes. The results
also demonstrated that the exclusion activity is strain specific,
since significant differences were also observed among strains
of the same species.
FIG. 1. Unweighted-pair group method using average linkages (UPGMA) dendrogram derived from similarity coefficients calculated by the
Jaccard method (simple Jaccard [Sj] coefficients; shown on the scale at the bottom), showing the relationship among Streptococcus salivarius
pharyngeal isolates, analyzed by BOX-PCR and RAPD analysis using primers M13, OPI02mod, OPI17mod, and PedAF. Samples with a similarity
coefficient higher than 0.9 have been included in the same genotype. Selected bacterial isolates included in antagonism experiments are indicated
in boldface.
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We found a correlation between the results obtained with
the two cell lines. In fact, with only a few exceptions, those
strains that significantly reduced the light production in
HaCaT cells also did so in the FaDu cell layer. Particularly, the
following two strains were the most active in both cell lines: S.
salivarius ST3 (with average reductions of bioluminescence of
40% in FaDu and 24% in HaCaT) and S. salivarius RS1
(33% in FaDu and 25% in HaCaT) (Fig. 3). Their activity
was significantly stronger than that of the S. salivarius K12
reference oral probiotic strain. Therefore, strains RS1 and ST3
were selected and included in all of the following experiments.
The antagonism by competition was tested only on the FaDu
cell layer for the two previously selected strains (S. salivarius
ST3 and RS1), the reference oral probiotic K12, and four other
strains (S. salivarius RS13, S. oralis ST4 and ST5p, and S.
sanguinis ST5g), which were selected in order to have at least
one representative strain for each of the four typologies of
bacterial adhesion on the FaDu layer (Fig. 2). In this experi-
ment, all tested strains markedly inhibited S. pyogenes biolu-
minescence, with particular evidence for S. salivarius strains
(	80% reduction) (Fig. 4). We also noticed a partial depen-
dence of competition on adhesion ability. The antagonism ef-
ficacy was in fact slightly weaker for poorly adhesive strains
(e.g., ST5p and ST5g) than strongly adhesive bacteria (e.g.,
K12 and ST3; P values of 
0.001, according to an unpaired
Student’s t test) (Fig. 4).
Inhibition of S. pyogenes and PCR detection of bacteriocin-
encoding genes. After 24 h of incubation at 37°C, we observed
clear inhibition zones corresponding to the colonies of the
tester strains K12, RS1, and ST3 (data not shown). On the
contrary, when cell-free neutralized broths were used in disk
diffusion tests, inhibition zones were observed only for the
reference strain S. salivarius K12. Accordingly, PCR experi-
ments suggested that strains RS1 and ST3 could not possess
bacteriocin genes, while strain K12 gave a positive signal for
two lantibiotics, salivaricins A and B (data not shown), which
are known to be carried by strain K12 on a 190-kb transmissi-
ble plasmid (22). In contrast, strains RS1 and ST3 are plasmid-
free strains (G. Ricci, personal communication). Therefore, it
appears plausible that the pharyngeal isolates ST3 and RS1
inhibited the growth of S. pyogenes in the plate probably simply
due to their acid production.
S. salivarius K12, RS1, and ST3 drive different immune
responses in vitro. Overnight incubation of a FaDu monolayer
with selected bacteria resulted in the modulation of cytokine
production profiles, as determined by the Bio-Plex human cy-
tokine 17-plex array system (Bio-Rad) (Table 2 and Fig. 5).
Under baseline conditions, the oral isolate S. salivarius RS1
nearly eliminated IL-1 secretion and reduced IL-6 and
TNF- in the FaDu supernatant from 78.1 to 42.0 pg ml1 and
from 1.9 to 0.6 pg ml1, respectively. Similarly, S. salivarius
ST3 eliminated the secretion of IL-1 and TNF- but, in
FIG. 2. Adhesion of bacterial strains to the FaDu epithelial cell layer according to their adhesion indexes (ADI; number of bacteria/100 FaDu
cells). (A) , strong adhesion (ADI of 2,500); , good adhesion (ADI of between 2,500 and 500); , weak adhesion (ADI of between 500
and 100);, no adhesion (ADI of
100). (B) Adhesion to FaDu cell monolayers, as observed with Giemsa staining under a light microscope. Bars,
8 m. One FaDu nucleus for each layer is indicated with the letter N.
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addition, enhanced the production of IL-8 (from 1,721 to 2,331
pg ml1), GM-CSF (from 0.2 to 1.9 pg ml1), and MIP-1
(from 0.9 to 3.2 pg ml1). The commercial oral probiotic Strep-
tococcus salivarius K12 decreased IL-6 and IL-8 at levels
greater than those of the other two streptococci (from 78.1 to
24.2 pg ml1 and from 1,721 to 579 pg ml1, respectively).
Furthermore, strain K12 induced a reduction of the secretion
of TNF- (from 1.9 to 0.9 pg ml1) and G-CSF (from 3.5 to 1.7
pg ml1) and increased GM-CSF (from 0.2 to 1.6 pg ml1)
(Table 2 and Fig. 5A).
When the FaDu layer was stimulated with 2 ng ml1 of the
proinflammatory cytokine IL-1, all strains tested noticeably
reduced the concentrations of IL-6 and IL-8 in the FaDu
culture supernatant. To be specific, strains K12, RS1, and ST3
reduced IL-6 from 121.5 to 73.7, 65.2, and 86.7 pg ml1, re-
spectively, and IL-8 from 3,353 to 2,043, 2,464, and 2,261 pg
ml1, respectively. Furthermore, S. salivarius RS1 induced a
reduction of IFN- secretion from 20.3 to 13.5 pg ml1 (Table
2 and Fig. 5B).
To further explore the immunomodulatory properties of
selected oral bacteria, we tested the effect of the microorgan-
isms on NF-B activation using a recombinant cell line, ob-
tained by transfecting FaDu cells with a luciferase reporter
vector inducible by NF-B. In FaDu cells, strains RS1 and ST3
showed at baseline a stimulatory effect on NF-B-dependent
production of bioluminescence. NF-B activation was partic-
ularly evident for strain ST3, which doubled the biolumines-
cence produced by FaDu cells when we employed an MOI of
about 1,000. In contrast, S. salivarius K12 did not significantly
affect NF-B at baseline (Fig. 6A).
In the series of experiments which followed, the effect of
bacterial strains on NF-B activation was assessed during stim-
ulation of FaDu cells with the proinflammatory cytokine IL-1.
The addition of 2 ng ml1 of IL-1 to FaDu culture medium
caused an almost 2-fold increase in NF-B activity after 4 h of
incubation. The IL-1-dependent increase in bioluminescence
was partially inhibited only at the highest MOI tested (1,000)
by S. salivarius strains K12 (38%), RS1 (34.5%), and ST3
(29.2%) (Fig. 6B).
Safety assessment of selected bacteria by antibiotic suscep-
tibility testing. We studied the antibiotic resistance of S. sali-
varius K12, RS1, and ST3 with reference to the European Food
Safety Authority (EFSA) breakpoints for Streptococcus ther-
mophilus (16), because S. salivarius is phylogenetically close to
S. thermophilus. Bacterial strains were found to be sensitive
to ampicillin, chloramphenicol, erythromycin, oxytetracycline,
and vancomycin. A variable resistance was observed with the
aminoglycoside antibiotics (gentamicin, kanamycin, and strep-
tomycin), depending on the strain and the growth medium. All
strains were assessed to be resistant to kanamycin, with the
only exception being S. salivarius ST3 grown in LM17 medium
(Table 3). Strain K12 was resistant to gentamicin in LM17
medium and to streptomycin in BHI medium. Strain RS1 dis-
played resistance to gentamicin in LM17 and MRS media and
to streptomycin in BHI and LM17 media. Finally, S. salivarius
ST3 was resistant to gentamicin in MRS medium and to strep-
tomycin in BHI and MRS media (Table 3).
ST3 is a natural urease-negative S. salivarius strain. The
potential safety of selected S. salivarius isolates was also tested,
considering their ability to hydrolyze urea. S. salivarius K12
and RS1 were markedly urealytic when grown in a medium
containing nickel cations. In contrast, strain ST3 did not hy-
drolyze urea. According to the phenotypic assay, we failed to
amplify from the strain ST3 ureC gene, which encodes the
alpha subunit protein containing the active site and conserved
nickel binding ligands of the urease complex. In contrast, a
PCR fragment of the expected length was obtained from the
FIG. 4. Antagonistic competition activity of bacterial pharyngeal
isolates against bioluminescent Streptococcus pyogenes C11LucFF on
FaDu hypopharyngeal carcinoma cells. Data reported as percent
variation of light emission, which referred to the cell layer treated
with only S. pyogenes cells. Numerical results are given as arithmetic
means  standard deviations. All samples resulted as being signif-
icantly different compared to the control (P 
 0.001, according to
an unpaired Student’s t test).
FIG. 3. Antagonistic exclusion activity of bacterial pharyngeal iso-
lates against bioluminescent Streptococcus pyogenes C11LucFF on FaDu
hypopharyngeal carcinoma cells (A) and HaCaT keratinocytes (B).
Data reported as percent variation of light emission, which referred to
the cell layer treated with only PBS buffer before incubation with S.
pyogenes. Numerical results are given as arithmetic means  standard
deviations. Each sample was processed in triplicate in at least two
independent experiments. Strains belonging to species S. salivarius are
indicated in boldface. Statistically significant differences compared to
strain K12 were calculated according to an unpaired Student’s t test
(**, P 
 0.001; *, P 
 0.05).
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other S. salivarius strains using primers targeting ureC (data
not shown).
DISCUSSION
Upper respiratory tract infections (URTIs) are the most
frequent reason for a visit to a pediatrician, and Streptococcus
pyogenes is a major cause of acute pharyngeal infections, espe-
cially in children 5 to 12 years of age (12). At present, the
treatment of acute bacterial pharyngitis consists of the ad-
ministration of broad-spectrum antibiotics. These have been
estimated to be prescribed in as high as 90% of the pediatric
visits for URTIs. A probiotic strategy effective in the pro-
phylaxis of pharyngitis, therefore, could provide a significant
social benefit.
In accordance with this objective, in this study we aimed to
select oral bacteria with potential probiotic features for the
pharyngeal mucosa. We included bacteria newly isolated from
the pharynges of healthy donors. Potentially, pharyngeal iso-
lates could, in fact, display better performances in the coloni-
zation of the oral ecosystem than traditional dairy or intestinal
probiotic bacteria.
In this research, half of the pharyngeal isolates were ascribed
to the species Streptococcus salivarius (28 out of 56 isolates), in
accordance with previous studies showing these bacteria to be
the dominant cultivable species in the oropharyngeal tract
(24). Nonpathogenic streptococci are the bacteria most largely
present at the oropharyngeal level, and they have been pro-
posed to exert a key role in the protection against pathogenic
agents, which cause inflammation and infections (39). In
particular, Streptococcus salivarius already becomes a stable
colonizer of the oral microbiota a few days after birth and
represents, in adults, the major species at the levels of the
pharyngeal mucosa and dorsal tongue.
The main criterion we adopted for the selection of potential
pharyngeal probiotics was the ability to antagonize Streptococ-
cus pyogenes on human epithelial cell layers. The experimental
system set up during this study consisted of the use of a re-
combinant S. pyogenes strain, expressing a firefly luciferase.
Since luciferase catalyzes a bioluminescent reaction that de-
pends stoichiometrically on ATP, the measurement of light
production, after addition of the substrate D-luciferin, is de-
pendent on both the number and the metabolic state of bac-
terial cells.
We also included in this part of the study immortalized
HaCaT cells that have been reported to retain many charac-
teristics of the human keratinocytes from which they were
originally derived (7). Keratinocytes are, in fact, a constitutive
part of the stratified oral epithelium and represent a primary
target of adhesion for invading S. pyogenes cells (1, 14). In
exclusion experiments, the ability of the tested bacteria to
antagonize S. pyogenes was found to be strain specific. In fact,
the most active strains on both of the epithelial layers were S.
salivarius RS1 and ST3, while strain SM12, belonging to the
same species, was unable to antagonize S. pyogenes.
Adhesion experiments performed on the FaDu cell layer can
give a partial explanation of the strong antagonizing activity
displayed by S. salivarius ST3 and RS1 (Fig. 3). Strains ST3 and
RS1, in fact, adhered efficiently to the epithelial layer (Fig. 2).
It can be hypothesized, therefore, that the competition for
adhesion sites is a major mechanism through which these bac-
teria antagonize S. pyogenes on FaDu cells.
One mechanism of action of probiotics is suggested to be
their modulation of host immune responses. In a recent study,
Cosseau and collaborators showed that the oral probiotic S.
salivarius K12 can induce in vitro anti-inflammatory responses
in epithelial cells, indicating a potential promotion of cellular
health and homeostasis (11). In that study, after coculture of
human bronchial epithelial cells (16HBE14O- cells) with strain
K12, they observed an inhibition of the baseline secretion of
the chemokine IL-8, in coincidence with the inhibition of the
activation of the NF-B pathway (11).
TABLE 2. Cytokine levels
Cytokine
Cytokine level (pg ml1) in EMEM culture brotha
Without IL-1 With IL-1
Control K12 RS1 ST3 Control K12 RS1 ST3
IL-1 8.60  0.85 9.50  0.54 0.34  0.37 0.77  0.25 254.2  3.3 298.1  64.1 204.7  20.0 229.8  18.7
IL-2 0.35  0.49 1.18  0.00 0.35  0.49 1.16  0.37 0.86  0.49 2.75  0.45 0.15  0.05 0.98  0.04
IL-4 0.22  0.01 0.15  0.21 0.19  0.19 0.21  0.09 0.27  0.04 0.76  0.06 0.57  0.16 0.46  0.03
IL-5 BDL BDL BDL BDL BDL BDL BDL BDL
IL-6 78.10  19.18 24.23  1.03 41.95  3.74 59.01  17.47 121.5  56.6 73.66  36.03 65.23  2.69 86.72  0.29
IL-7 0.28  0.03 0.20  0.28 0.45  0.26 0.86  0.27 0.61  0.23 0.37  0.06 0.83  0.12 0.46  0.22
IL-8 1,721  565 579,0  134.7 1,547  327 2,331  402 3,353  872 2,043  124 2,464  213 2,261  357
IL-10 0.07  0.10 0.26  0.04 0.02  0.03 0.16  0.22 BDL 0.33  0.22 BDL 0.15  0.05
IL-12 (p70) 0.40  0.57 0.80  0.28 0.34  0.07 BDL BDL 1.95  1.06 0.60  0.85 0.70  0.14
IL-13 0.61  0.09 0.36  0.01 0.09  0.03 0.18  0.25 0.21  0.05 1.16  0.37 0.48  0.04 0.67  0.11
IL-17 0.29  0.17 0.94  0.36 0.47  0.66 0.91  0.21 0.32  0.028 3.08  0.77 1.66  0.57 2.06  0.57
G-CSF 3.45  0.67 1.67  0.08 1.65  1.73 2.06  0.72 9.55  2.52 7.62  0.41 5.02  1.08 13.14  5.17
GM-CSF 0.19  0.01 1.59  0.28 1.17  0.98 1.85  0.65 2.84  0.75 5.55  2.12 2.88  0.95 2.37  0.51
IFN- 10.83  4.60 9.42  0.86 10.90  2.09 8.38  4.82 20.31  4.12 28.54  0.35 13.52  0.21 22.11  5.90
MCP-1 1.13  0.28 0.58  0.81 1.39  0.87 2.09  0.85 3.08  0.66 3.36  0.40 2.57  0.02 2.73  0.45
MIP-1 0.92  0.38 0.25  0.18 1.08  0.79 3.23  0.63 1.79  0.24 2.46  0.76 2.37  1.59 3.54  0.97
TNF- 1.88  0.62 0.86  0.17 0.62  0.52 BDL 3.51  0.15 5.99  1.87 3.18  1.51 7.26  1.49
a Determined by using Bio-Plex assays after overnight incubation of FaDu layers in the presence of bacterial cells (2  108 cells ml1) with or without IL-1 (2 ng
ml1). Control samples were obtained by incubating FaDu layers without bacterial cells. BDL, below detection limit.
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In our study, the immunomodulatory properties of S. sali-
varius K12, RS1, and ST3 were tested on a FaDu layer by
means of ELISA quantification of 17 secreted cytokines.
Subsequently, in order to elucidate the possible mechanisms
involved in the effects on cytokine production, we studied the
modulation of NF-B activation.
In these experiments, none of the tested strains exhibited
potential proinflammatory effects, suggesting that they could
be well tolerated by human epithelial cells in vivo. This state-
ment is consistent with the induced reduction of baseline
TNF- secretion, which was observed with all tested strains. In
details, we found two different behaviors among the bacteria
under study. While strain K12 reduced baseline IL-8 and IL-6
secretion, in contrast, RS1 and ST3 inhibited drastically IL-1
and stimulated the MIP-1 and MCP-1 cytokines. These re-
sults have been partially explained by the experiments on
NF-B activation. The reduced secretion of IL-8 and IL-6
provoked by strain K12 can be attributed to the inhibition of
NF-B activation, as already proposed by Cosseau et al. (11).
In contrast, S. salivarius RS1 and ST3 promoted the baseline
activation of NF-B. Greten and collaborators have recently
demonstrated that NF-B activates the secretion of a selective
FIG. 5. Cytokine secretions that changed significantly after treatment of the FaDu layer with bacterial cells, as determined by using the Bio-Plex
assay. The same results are also included in Table 2. FaDu layers were incubated overnight with bacterial cells (2 108 cells ml1) without (A) and
in the presence of (B) 2 ng ml1 of IL-1. The values are the means from two experiments conducted in duplicate. The vertical bars indicate
standard deviations.
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inhibitor of caspase-1, a peptidase required for pro-IL-1 mat-
uration (18). Therefore, we can reasonably speculate that the
inhibition of IL-1 secretion by strains RS1 and ST3 could also
be mediated by a mechanism involving inhibition of the en-
zyme caspase-1. The oral S. salivarius isolates RS1 and ST3,
additionally, stimulated the secretion of MIP-1 and MCP-1
by FaDu cells. Similar behavior has been previously described
for the well-known intestinal probiotic Escherichia coli Nissle
1917 (40). Even if MIP-1 and MCP-1 are proinflammatory
cytokines, it has been proposed that, upon contact with com-
mensal microbes, local induction of proinflammatory immune
responses by way of the upregulation of the MCP-1 and MIP
cytokines might reflect part of the host defense process against
pathogenic bacteria by establishing a protective immunological
barrier (40).
Cytokine secretion and modulation of NF-B activity by
selected bacteria were also tested on FaDu cells stimulated
with IL-1, a prototypical proinflammatory cytokine that plays
a central role in the inflammation amplification cascade. After
stimulation by IL-1, we observed that, at an MOI of 1,000,
strains K12, RS1, and ST3 reduced the NF-B activation in a
statistically significant manner, while the other conditions
tested had no significant effect. The stimulatory activity of RS1
and ST3 bacterial cells on NF-B activation was, therefore,
eliminated in the presence of the inflammatory stimulus due to
IL-1. Similarly, it is noteworthy that in IL-1-treated FaDu
cells, S. salivarius strains can considerably reduce IL-6 and IL-8
secretion, suggesting their potential anti-inflammatory activity.
Recently, the European Food Safety Authority (EFSA) as-
signed a “Qualified Presumption of Safety” (QPS) status (15)
to several lactic acid bacterial species, including Streptococcus
thermophilus but not Streptococcus salivarius. In Europe, S.
salivarius belongs to risk group 2 (like S. pyogenes or S. pneu-
moniae), while the very closely related Streptococcus species S.
thermophilus, S. uberis, and S. vestibularis (32) belong to risk
group 1. Presumably, S. salivarius is considered an opportunis-
tic pathogen because, as with many food-grade lactobacilli,
there have been sporadic reports of infections, generally in
subjects under adverse medical conditions (2, 3, 10). Quite the
opposite, in other parts of the world, S. salivarius has already
acquired the status of safe microorganism and has been com-
mercialized for several years as a probiotic without any re-
FIG. 6. Effects of selected bacterial strains on FaDu cells stably
transfected with an NF-B/luciferase reporter vector, without (A) or
with (B) stimulation with IL-1 (2 ng ml1). Luciferase activity is
expressed as percent change of relative luminescence units (RLU),
assuming the control as 100%. Control, FaDu layers incubated without
bacterial cells. The values are the means ( standard deviations) from
at least three independent experiments conducted in duplicate. Aster-
isks indicate statistically significant differences compared to the con-
trol. MOI, multiplicity of infection (bacterial cells per FaDu cell).




(g ml1)bK12 RS1 ST3






























16 <64 >64 
16 
8 >64 32
16 8 >32 8











Streptomycin1 <128, >64 
16 <128, >64 <128, >64 
64, 32 <128, >64 










a Possible interference of the growth medium is reported (16).
b Microbiological breakpoints categorizing bacteria as resistant, according to EFSA guidelines for Streptococcus thermophilus (16).
c MICs above EFSA limits are in boldface. LM17, M17 medium containing 2% lactose.
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ported adverse consequences (9). In the light of the above-
mentioned facts, the optimal strategy to assess the safety of S.
salivarius would be considering every specific strain indepen-
dently, in accordance with FAO/WHO guidelines on probiotics
(17), as has been done for S. salivarius strain K12 (9, 11). From
this perspective, the absence of transmissible antibiotic resis-
tances is considered a key safety prerequisite for the selection
of a probiotic microorganism (15, 17). In this study, S. saliva-
rius strains, according to the EFSA breakpoints suggested for
S. thermophilus, resulted in sensitivity to a variety of antibiotics
that are routinely used for the control of URTIs. Differently,
they showed resistance exclusively to the aminoglycosidic an-
tibiotics gentamicin, kanamycin, and streptomycin, for which
an intrinsic resistance is known for several lactic acid bacteria
(10, 16, 21, 30).
Another bacterial feature that exerts an important role in
the interaction with the human host is urease activity. Ammo-
nia production from ureolysis in saliva and crevicular fluids is,
in fact, a primary source of amino nitrogen and is thought to
inhibit the initiation and progression of dental caries by reduc-
ing acidity (26, 33). At the same time, a high concentration of
ammonia can have deleterious effects on host cells (19), such
as fibroblasts and polymorphonuclear leukocytes, and may
therefore contribute to tissue damage (19). Among the species
of oral bacteria that have been identified as ureolytic, S. sali-
varius is known to produce high levels of urease (37). Unex-
pectedly, S. salivarius strain ST3, selected for this work for its
potential probiotic properties, was unable to hydrolyze urea.
Accordingly, the gene coding for the main subunit of the ure-
ase complex (ureC) was missing. In the consideration of its use
as the pharynx’s probiotic, this bacterium would interact di-
rectly with oropharyngeal mucosae and tonsil crypts. There-
fore, the inability to hydrolyze urea could be of potential ben-
efit in preserving the host’s mucosal cells from ammonia injury.
In summary, during this research, an in vitro rational process
led us to select two potential probiotic bacterial strains for the
pharynx mucosa. These bacteria efficiently adhered to human
epithelial pharyngeal cell lines, antagonizing the adhesion of
Streptococcus pyogenes. Furthermore, immunological tests sug-
gested a good degree of adaptation to the host and potential
immunomodulatory and anti-inflammatory abilities by selected
commensal streptococci. Future work will aim to characterize
the probiotic potential of these bacteria in the oral tract by
means of in vivo murine models of upper respiratory tract
infections.
ACKNOWLEDGMENTS
We thank Elisa Bertolasi and Giovanni Ricci for technical support.
Special thanks go to Marco Oggioni for providing Streptococcus pyo-
genes C11.
Part of this study was financed by PUR 2008.
REFERENCES
1. Abbot, E. L., W. D. Smith, G. P. Siou, C. Chiriboga, R. J. Smith, J. A. Wilson,
B. H. Hirst, and M. A. Kehoe. 2007. Pili mediate specific adhesion of Strep-
tococcus pyogenes to human tonsil and skin. Cell. Microbiol. 9:1822–1833.
2. Afek, S., A. D. Sperber, and Y. Almog. 2004. Carcinoma of the colon pre-
senting as Streptococcus salivarius sepsis. J. Clin. Gastroenterol. 38:86–87.
3. Ahmed, R., T. Hassall, B. Morland, and J. Gray. 2003. Viridans streptococ-
cus bacteremia in children on chemotherapy for cancer: an underestimated
problem. Pediatr. Hematol. Oncol. 20:439–444.
4. Beimfohr, C., W. Ludwig, and K. H. Schleifer. 1997. Rapid genotypic dif-
ferentiation of Lactococcus lactis subspecies and biovar. Syst. Appl. Micro-
biol. 20:216–221.
5. Bek-Thomsen, M., H. Tettelin, I. Hance, K. E. Nelson, and M. Kilian. 2008.
Population diversity and dynamics of Streptococcus mitis, Streptococcus oralis,
and Streptococcus infantis in the upper respiratory tracts of adults, deter-
mined by a nonculture strategy. Infect. Immun. 76:1889–1896.
6. Borchert, D., L. Sheridan, A. Papatsoris, Z. Faruquz, J. M. Barua, I. Junaid,
Y. Pati, F. Chinegwundoh, and N. Buchholz. 2008. Prevention and treatment
of urinary tract infection with probiotics: review and research perspective.
Indian J. Urol. 24:139–144.
7. Boukamp, P., R. T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham,
and N. E. Fusenig. 1988. Normal keratinization in a spontaneously immor-
talized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761–771.
8. Burton, J. P., C. N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg. 2006.
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on
oral malodour parameters. J. Appl. Microbiol. 100:754–764.
9. Burton, J. P., P. A. Wescombe, C. J. Moore, C. N. Chilcott, and J. R. Tagg.
2006. Safety assessment of the oral cavity probiotic Streptococcus salivarius
K12. Appl. Environ. Microbiol. 72:3050–3053.
10. Corredoira, J. C., M. P. Alonso, J. F. Garcia, E. Casariego, A. Coira, A.
Rodriguez, J. Pita, C. Louzao, B. Pombo, M. J. Lopez, and J. Varela. 2005.
Clinical characteristics and significance of Streptococcus salivarius bacter-
emia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur.
J. Clin. Microbiol. Infect. Dis. 24:250–255.
11. Cosseau, C., D. A. Devine, E. Dullaghan, J. L. Gardy, A. Chikatamarla, S.
Gellatly, L. L. Yu, J. Pistolic, R. Falsafi, J. R. Tagg, and R. E. Hancock. 2008.
The commensal Streptococcus salivarius K12 downregulates the innate im-
mune responses of human epithelial cells and promotes host-microbe ho-
meostasis. Infect. Immun. 76:4163–4175.
12. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections.
Clin. Microbiol. Rev. 13:470–511.
13. Eberl, G., and M. Lochner. 2009. The development of intestinal lymphoid
tissues at the interface of self and microbiota. Mucosal Immunol. 2:478–485.
14. Edwards, M. L., P. K. Fagan, R. J. Towers, B. J. Currie, and K. S. Sri-
prakash. 2004. Inhibition of Streptococcus pyogenes adherence to HaCaT
cells by a peptide corresponding to the streptococcal fibronectin-binding
protein, SfbI, is strain dependent. Microbes Infect. 6:926–928.
15. EFSA. 13-14 December 2004. Scientific Colloquium Summary Report. QPS:
qualified presumption of safety of microorganisms in food and feed. EFSA,
Brussels, Belgium.
16. EFSA. 2008. Update of the criteria used in the assessment of bacterial
resistance to antibiotics of human or veterinary importance. Prepared by the
Panel on Additives and Products or Substances Used in Animal Feed. EFSA
J. 732:1–15.
17. FAO/WHO. 2002. Report of a joint FAO/WHO expert consultation on
guidelines for the evaluation of probiotics in food. World Health Organiza-
tion and Food and Agriculture Organization of the United Nations, London
Ontario, Canada.
18. Greten, F. R., M. C. Arkan, J. Bollrath, L. C. Hsu, J. Goode, C. Miething,
S. I. Goktuna, M. Neuenhahn, J. Fierer, S. Paxian, N. Van Rooijen, Y. Xu,
T. O’Cain, B. B. Jaffee, D. H. Busch, J. Duyster, R. M. Schmid, L. Eckmann,
and M. Karin. 2007. NF-B is a negative regulator of IL-1 secretion as
revealed by genetic and pharmacological inhibition of IKK. Cell 130:918–
931.
19. Helgeland, K. 1985. pH and the effect of NH4Cl on human gingival fibro-
blasts. Scand. J. Dent. Res. 93:39–45.
20. Horz, H. P., A. Meinelt, B. Houben, and G. Conrads. 2007. Distribution and
persistence of probiotic Streptococcus salivarius K12 in the human oral cavity
as determined by real-time quantitative polymerase chain reaction. Oral
Microbiol. Immunol. 22:126–130.
21. Hummel, A. S., C. Hertel, W. H. Holzapfel, and C. M. Franz. 2007. Antibiotic
resistances of starter and probiotic strains of lactic acid bacteria. Appl.
Environ. Microbiol. 73:730–739.
22. Hyink, O., P. A. Wescombe, M. Upton, N. Ragland, J. P. Burton, and J. R.
Tagg. 2007. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded
at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral
probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol. 73:
1107–1113.
23. Johnson-Henry, K. C., D. J. Mitchell, Y. Avitzur, E. Galindo-Mata, N. L.
Jones, and P. M. Sherman. 2004. Probiotics reduce bacterial colonization
and gastric inflammation in H. pylori-infected mice. Dig. Dis. Sci. 49:1095–
1102.
24. Kang, J. G., S. H. Kim, and T. Y. Ahn. 2006. Bacterial diversity in the human
saliva from different ages. J. Microbiol. 44:572–576.
25. Kelly, K. 1994. Out of control: the new biology of machines, social systems
and the economic world. Addison-Wesley, Boston, MA.
26. Kleinberg, I. 1967. Effect of urea concentration on human plaque pH levels
in situ. Arch. Oral Biol. 12:1475–1484.
27. Krutmann, J. 2009. Pre- and probiotics for human skin. J. Dermatol. Sci.
54:1–5.
28. Lanyi, B. 1987. Classical and rapid identification: methods for medically
important bacteria, p. 1–67. In R. R. Colwell and R. Grigorova (ed.), Meth-
ods in microbiology, vol. 19. Academic Press, New York, NY.
29. Loimaranta, V., J. Tenovuo, L. Koivisto, and M. Karp. 1998. Generation of
VOL. 76, 2010 LABs AS PROBIOTICS FOR THE PHARYNX 3957












bioluminescent Streptococcus mutans and its usage in rapid analysis of the
efficacy of antimicrobial compounds. Antimicrob. Agents Chemother. 42:
1906–1910.
30. Maragkoudakis, P. A., M. Papadelli, M. Georgalaki, E. G. Panayotopoulou,
B. Martinez-Gonzalez, A. F. Mentis, K. Petraki, D. N. Sgouras, and E.
Tsakalidou. 2009. In vitro and in vivo safety evaluation of the bacteriocin
producer Streptococcus macedonicus ACA-DC 198. Int. J. Food Microbiol.
133:141–147.
31. Mora, D., E. Maguin, M. Masiero, C. Parini, G. Ricci, P. L. Manachini, and
D. Daffonchio. 2004. Characterization of urease genes cluster of Streptococ-
cus thermophilus. J. Appl. Microbiol. 96:209–219.
32. Mora, D., G. Ricci, S. Guglielmetti, D. Daffonchio, and M. G. Fortina. 2003.
16S-23S rRNA intergenic spacer region sequence variation in Streptococcus
thermophilus and related dairy streptococci and development of a multiplex
ITS-SSCP analysis for their identification. Microbiology 149:807–813.
33. Peterson, S., J. Woodhead, and J. Crall. 1985. Caries resistance in children
with chronic renal failure: plaque pH, salivary pH, and salivary composition.
Pediatr. Res. 19:796–799.
34. Power, D. A., J. P. Burton, C. N. Chilcott, P. J. Dawes, and J. R. Tagg. 2008.
Preliminary investigations of the colonisation of upper respiratory tract tis-
sues of infants using a paediatric formulation of the oral probiotic Strepto-
coccus salivarius K12. Eur. J. Clin. Microbiol. Infect. Dis. 27:1261–1263.
35. Proal, A. D., P. J. Albert, and T. Marshall. 2009. Autoimmune disease in the
era of the metagenome. Autoimmun. Rev. 8:677–681.
36. Reid, G., J. Dols, and W. Miller. 2009. Targeting the vaginal microbiota with
probiotics as a means to counteract infections. Curr. Opin. Clin. Nutr.
Metab. Care 12:583–587.
37. Sissons, C. H., and T. W. Cutress. 1987. In-vitro urea-dependent pH-changes
by human salivary bacteria and dispersed, artificial-mouth, bacterial plaques.
Arch. Oral Biol. 32:181–189.
38. Tagg, J. R. 2004. Prevention of streptococcal pharyngitis by anti-Streptococ-
cus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Strep-
tococcus salivarius. Indian J. Med. Res. 119(Suppl.):13–16.
39. Tagg, J. R., and K. P. Dierksen. 2003. Bacterial replacement therapy:
adapting ‘germ warfare’ to infection prevention. Trends Biotechnol. 21:
217–223.
40. Ukena, S. N., A. M. Westendorf, W. Hansen, M. Rohde, R. Geffers, S.
Coldewey, S. Suerbaum, J. Buer, and F. Gunzer. 2005. The host response to
the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the
proinflammatory chemokine MCP-1. BMC Med. Genet. 6:43.
41. Wescombe, P. A., J. P. Burton, P. A. Cadieux, N. A. Klesse, O. Hyink, N. C.
Heng, C. N. Chilcott, G. Reid, and J. R. Tagg. 2006. Megaplasmids encode
differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van
Leeuwenhoek 90:269–280.
42. Zilber-Rosenberg, I., and E. Rosenberg. 2008. Role of microorganisms in the
evolution of animals and plants: the hologenome theory of evolution. FEMS
Microbiol. Rev. 32:723–735.
3958 GUGLIELMETTI ET AL. APPL. ENVIRON. MICROBIOL.
 by on June 8, 2010 
a
e
m
.a
sm
.o
rg
D
ow
nloaded from
 
